Short answer: Willow sells compounded semaglutide for $299 a month all-in, and Hims sells FDA-approved GLP-1s from $298 a month all-in. For…
September 22, 2026
SweetSpot Health
Quick verdict
- Best for
- diabetes clinics and practices seeking one view of patients’ CGM and insulin-pump data
- Key feature
- SweetSpot is a diabetes data-management and remote-care platform for healthcare practices. Its software consolidates continuous-glucose-monitor and insulin-pump data, while its clinical-support team helps partner practices monitor patients and coordinate follow-up. It is not a weight-loss clinic or consumer GLP-1 prescriber.
SweetSpot is a diabetes data-management and remote-care platform for healthcare practices. Its software consolidates continuous-glucose-monitor and insulin-pump data, while its clinical-support team helps partner practices monitor patients and coordinate follow-up. It is not a weight-loss clinic or consumer GLP-1 prescriber. Published pricing: SweetSpot states there is no setup fee or monthly subscription fee for practice partners; the public site does not publish a complete commercial rate card or a consumer price. This independent directory review evaluates public information, not medical outcomes. We did not purchase the service or test medication. Eligibility, prices and terms may change; verify them directly before making a care decision.
Our rating
Pros and cons
Pros
- diabetes clinics and practices seeking one view of patients’ CGM and insulin-pump data
- The company publishes a service description that informs pre-enrollment questions.
- Virtual or integrated care may be convenient for eligible users.
Cons
- Best assessed as a provider-side tool; individual patients generally interact through their care team, and access depends on a clinic partnership.
- SweetSpot states there is no setup fee or monthly subscription fee for practice partners; the public site does not publish a complete commercial rate card or a consumer price.
- Public information does not guarantee individual eligibility or outcomes.
About this product
SweetSpot is a diabetes data-management and remote-care platform for healthcare practices. Its software consolidates continuous-glucose-monitor and insulin-pump data, while its clinical-support team helps partner practices monitor patients and coordinate follow-up. It is not a weight-loss clinic or consumer GLP-1 prescriber.
How it compares
Short answer: both mainly sell compounded GLP-1s, which are not FDA-approved. Mochi Health is cheaper at low doses, from $139 a month…
September 22, 2026
Short answer: Hims and Noom are different kinds of programs. Hims sells FDA-approved brand-name GLP-1s with a $149 membership, from $298 a…
September 22, 2026
User reviews
No user reviews yet.